Cite
Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study
MLA
Taplin, Mary-Ellen, et al. “Prognostic Significance of Plasma Chromogranin a Levels in Patients with Hormone-Refractory Prostate Cancer Treated in Cancer and Leukemia Group B 9480 Study.” Urology, vol. 66, no. 2, Aug. 2005, pp. 386–91. EBSCOhost, https://doi.org/10.1016/j.urology.2005.03.040.
APA
Taplin, M.-E., George, D. J., Halabi, S., Sanford, B., Febbo, P. G., Hennessy, K. T., Mihos, C. G., Vogelzang, N. J., Small, E. J., & Kantoff, P. W. (2005). Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology, 66(2), 386–391. https://doi.org/10.1016/j.urology.2005.03.040
Chicago
Taplin, Mary-Ellen, Daniel J. George, Susan Halabi, Ben Sanford, Philip G. Febbo, Kristen T. Hennessy, Christos G. Mihos, Nicholas J. Vogelzang, Eric J. Small, and Philip W. Kantoff. 2005. “Prognostic Significance of Plasma Chromogranin a Levels in Patients with Hormone-Refractory Prostate Cancer Treated in Cancer and Leukemia Group B 9480 Study.” Urology 66 (2): 386–91. doi:10.1016/j.urology.2005.03.040.